Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
Hillner
Bruce E
BE
Smith
Thomas J
TJ
D000368:Aged; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000401:mortality*; D017024:Chemotherapy, Adjuvant / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D000068878:Trastuzumab; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab